创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

朱峻良, 戴权, 朱韧, 龙思会, 余文颖. 新型冠状病毒感染治疗药物研究进展[J]. 药学进展, 2023, 47(7): 519-531. DOI: 10.20053/j.issn1001-5094.2023.07.007
引用本文: 朱峻良, 戴权, 朱韧, 龙思会, 余文颖. 新型冠状病毒感染治疗药物研究进展[J]. 药学进展, 2023, 47(7): 519-531. DOI: 10.20053/j.issn1001-5094.2023.07.007
ZHU Junliang, DAI Quan, ZHU Ren, LONG Sihui, YU Wenying. Advances in Research on Drugs for Treatment of COVID-19[J]. Progress in Pharmaceutical Sciences, 2023, 47(7): 519-531. DOI: 10.20053/j.issn1001-5094.2023.07.007
Citation: ZHU Junliang, DAI Quan, ZHU Ren, LONG Sihui, YU Wenying. Advances in Research on Drugs for Treatment of COVID-19[J]. Progress in Pharmaceutical Sciences, 2023, 47(7): 519-531. DOI: 10.20053/j.issn1001-5094.2023.07.007

新型冠状病毒感染治疗药物研究进展

Advances in Research on Drugs for Treatment of COVID-19

  • 摘要: 新型冠状病毒(SARS-CoV-2)疫情自发生以来,给全球公共卫生安全和经济带来了巨大冲击。如今,全球抗疫已取得阶段性成果,SARS-CoV-2疫情也不再构成“国际关注的突发公共卫生事件”,但并不意味着SARS-CoV-2流行的结束。SARS-CoV-2感染(COVID-19)治疗药物的研发不仅不应停止,还需要更进一步的探索。简介SARS-CoV-2的感染机制,并对基于病毒和宿主细胞的靶标的COVID-19治疗药物研究进展进行综述。

     

    Abstract: The SARS-CoV-2 pandemic has brought tremendous impact on global public health security and economy since its outbreak. At present, the global anti-epidemic efforts have achieved phased results, and the SARS-CoV-2 epidemic no longer constitutes "a Public Health Emergency of International Concern", but this does not mean that the SARS-CoV-2 epidemic has ended. The research and development of COVID-19 therapeutic drugs should not only continue, but also need to be further explored. In this article, the infection mechanism of SARS-CoV-2 has been briefly introduced, and the research progress of COVID-19 therapeutic drugs based on virus and host cell targets has also been reviewed.

     

/

返回文章
返回